This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Indication:
Topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes
Mechanism of action:
Inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol and altering the fungal cell membranes 
Comparative agents: Linezolid

Indication:
Adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria
Mechanism of action:
Binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis 
Comparative agents: Natalizumab
Indication: Treatment for adults with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for inducing and maintaining clinical response; inducing and maintaining clinical remission; improving endoscopic appearance of the mucosa; or achieving corticosteroid-free remission. Vedolizumab is also approved for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for achieving clinical response, achieving clinical remission, or achieving corticosteroid-free remission.
Mechanism of action:
Antagonizes the alpha-4 beta-7 integrin and inhibits binding of the alpha-4 beta-7 integrin to the intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1) 
